Insulin degludec and liraglutide Subcutaneous and Miglitol
Determining the interaction of Insulin degludec and liraglutide Subcutaneous and Miglitol and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using insulin degludec together with miglitol can increase the risk of hypoglycemia (low blood sugar). Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, weakness, tremor, nausea, hunger, sweating, and fast or pounding heartbeats. You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications. Because miglitol prevents the breakdown of table sugar, a source of glucose (dextrose, D-glucose) should be readily available to treat symptoms of hypoglycemia. Severe cases may require an intravenous glucose infusion or glucagon injection. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSE: Miglitol may potentiate the risk of hypoglycemia associated with the use of sulfonylureas or insulin. When administered alone, miglitol does not typically cause hypoglycemia in the fasted or postprandial state. However, because concomitant administration results in a further lowering of blood glucose, miglitol may increase the hypoglycemic potential of sulfonylureas and insulin.
MANAGEMENT: Dosage reduction of sulfonylureas and insulin should be considered when prescribed in combination with miglitol. Because miglitol inhibits the hydrolysis of sucrose to glucose and fructose, a source of glucose (dextrose, D-glucose) should be readily available to treat mild to moderate hypoglycemia. Severe hypoglycemia may require the use of either intravenous glucose infusion or glucagon injection
- "Product Information. Glyset (miglitol)." Bayer, West Haven, CT.
Generic Name: insulin degludec / liraglutide
Brand name: Xultophy
Synonyms: Insulin degludec and liraglutide (Subcutaneous)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin degludec and liraglutide Subcutaneous-Miglustat
- Insulin degludec and liraglutide Subcutaneous-Migranal
- Insulin degludec and liraglutide Subcutaneous-Migranal nasal
- Insulin degludec and liraglutide Subcutaneous-MigraTen
- Insulin degludec and liraglutide Subcutaneous-Milantex
- Insulin degludec and liraglutide Subcutaneous-Mili
- Miglitol-Insulin degludec Subcutaneous
- Miglitol-Insulin detemir
- Miglitol-Insulin Detemir (Cartridges and Prefilled Syringes)
- Miglitol-Insulin Detemir (Vials)
- Miglitol-Insulin detemir Subcutaneous
- Miglitol-Insulin glargine